LPCN 1144 Resolves NAFLD in Hypogonadal Males
Somaya Albhaisi, Kilyoung Kim, Jonathan Baker, Nachiappan Chidambaram, Mahesh V. Patel, Michael Charlton, Arun J. Sanyal – 2 August 2020 – Hypogonadism affects hepatic lipid metabolism and is expected to promote nonalcoholic fatty liver disease (NAFLD). The aims of this study were to determine (1) the prevalence of NAFLD in hypogonadal males and (2) the impact of correction of hypogonadism by LPCN 1144 (Lipocine, Inc., Salt Lake City, UT), an oral testosterone prodrug, on NAFLD in this population.